Editorial Standards · Medical Review · Trust

Editorial Standards & Medical Review Process

Last updated May 16, 2026

RangeYourself is an independent consumer-research publication that compares GLP-1 telehealth programs. This page explains how we evaluate providers, how we keep claims consistent with FDA labeling and recognized clinical guidance, how we distinguish compounded from brand-name medication, how we correct errors, and how editorial work stays separate from affiliate relationships.

This is consumer research, not medical advice. We do not prescribe medication, diagnose conditions, recommend a dose, or tell readers which treatment is appropriate for them. GLP-1 medications require medical oversight, and decisions about them should be made with a licensed clinician.

Our standards exist so a reader can see why a program ranks where it does, what a claim is based on, and where money enters the picture.

Editorial Independence

RangeYourself earns money when readers sign up or purchase through certain provider links. Those affiliate commissions fund the research, comparison, writing, and ongoing maintenance the site requires. They do not buy rankings.

We work only with established affiliate networks and direct programs: Katalys, Awin, CJ Affiliate, and Amazon Associates. We do not accept payment for a specific placement, we do not raise a provider because its commission is higher, and we do not soften documented drawbacks because a partner prefers gentler language. A provider can be an affiliate partner and still rank below a non-partner when the comparison supports that result. See our Affiliate Disclosure for the full statement.

How We Evaluate GLP-1 Providers

Rankings are editorial judgments based on a weighted set of criteria, not a single formula and not affiliate payout. The core standards are:

Pricing transparency. Whether the program states a clear monthly cost, separates membership from medication, discloses dose-based price changes, and makes cancellation and refill terms visible before checkout.
Medication pathway clarity. Whether the provider clearly distinguishes compounded semaglutide or tirzepatide from brand-name GLP-1 medications, and whether eligibility and substitution rules are explained.
Clinical oversight. Whether licensed clinicians are part of intake and follow-up, whether eligibility screening is described, and whether the provider explains who the program is and is not appropriate for.
Insurance and accessibility. Whether the program is cash-pay or bills insurance, whether it helps with prior authorization, and which states it serves.
Evidence and responsible claims. Whether provider claims are stated responsibly, consistent with available evidence, and free of guaranteed-outcome language.

The full data-collection process, confidence levels, and transparency scoring are documented in our methodology. A program can be affordable and still rank lower if its public pricing structure is hard for a consumer to understand before signing up.

Medical & Regulatory Alignment

When we describe a brand-name GLP-1 medication, we keep claims consistent with that medication’s FDA-approved labeling and approved indications. We do not present off-label use as approved use, and we do not state or imply that a prescription, approval, or particular outcome is guaranteed.

Where we describe clinical context — eligibility considerations, dose escalation, monitoring, or who a program may not be appropriate for — we keep that framing consistent with recognized clinical guidance, including American Association of Clinical Endocrinology (AACE) guidelines for obesity and pharmacologic management. We reference these for general consumer context only; they do not constitute clinical direction from RangeYourself.

Compounded vs. Brand-Name Medication

Brand-name GLP-1 medications — Ozempic, Wegovy, Mounjaro, and Zepbound — are FDA-approved finished products for specific indications. Compounded GLP-1 medications are prepared by licensed pharmacies and are not FDA-approved finished products, even when legally dispensed.

We distinguish the regulatory category of the compounding source where it is relevant: 503A pharmacies compound for individual patient prescriptions, while 503B outsourcing facilities register with the FDA and are subject to current good manufacturing practice requirements. Either way, compounded semaglutide or tirzepatide is not the same as the brand-name product, and we never describe them as equivalent. These pathways are labeled separately throughout our coverage because their cost structure, insurance role, and clinical considerations differ.

No Prescription or Medical Guidance

RangeYourself does not provide prescription guidance. We do not tell readers whether they qualify for treatment, which medication to take, what dose is appropriate, or whether compounded or brand-name medication is right for them. We do not facilitate prescriptions and we do not guarantee that any reader will be approved for a program.

Eligibility, dosing, and treatment decisions are made by licensed clinicians through the provider, subject to medical evaluation. Readers should consult a licensed clinician before starting, stopping, or changing any prescription weight-loss treatment.

Fact-Checking & Verification

Pricing and program details are verified against the provider’s public-facing pages, pricing pages, FAQs, and checkout or onboarding language where accessible. Every pricing claim is tied to a verification date, and we label confidence where pricing is not fully clear from public information.

We cite primary sources — FDA resources, provider documentation, and recognized clinical guidance — rather than aggregators, and we do not publish citations we cannot substantiate. Where evidence is limited or pricing is unclear, we say so rather than overstate.

Corrections Policy

When we identify a factual or pricing error, we correct the affected page promptly. Material corrections — those that change a ranking, a price, or a safety-relevant statement — are recorded in the page’s update log with the date of the change so readers can see what was revised. Readers can report a suspected error to editorial@rangeyourself.com.

Update & Freshness Policy

GLP-1 telehealth pricing, availability, and program terms change often. We aim to review core comparison and pricing pages regularly and to update the GLP-1 Price Index when material changes are found. A page’s last-updated date reflects when our editorial process last reviewed it. It does not guarantee that a provider has not changed its terms since that date, so readers should still confirm final details on the provider’s site before purchasing.

Credentialed Review Status

RangeYourself is a consumer-research publication. Our GLP-1 content is written and edited from a consumer-comparison perspective, not as medical guidance. Unless a page specifically states otherwise, content has not been reviewed by a physician, pharmacist, or other credentialed medical professional. When credentialed review is added to a page, we identify the reviewer’s role and the scope of the review.

Update Log

May 16, 2026:Editorial Standards & Medical Review page published. Documented editorial independence and approved affiliate networks, GLP-1 evaluation criteria, FDA labeling and AACE alignment, compounded vs. brand-name (503A / 503B) distinction, no-prescription-guidance statement, fact-checking, corrections policy, and freshness policy.

Frequently Asked Questions

Does RangeYourself provide medical advice?

No. RangeYourself publishes consumer research and price comparison information. We do not diagnose conditions, prescribe medication, recommend a dose, or determine whether any GLP-1 treatment is medically appropriate for an individual. Medical decisions about GLP-1 medications should be made with a licensed clinician.

Do affiliate commissions influence RangeYourself rankings?

No. Affiliate commissions fund the research and editorial operation, but they do not determine rankings or recommendations. A provider can rank below a non-partner if its pricing is unclear, its terms are weaker, or another program is a better fit for the reader. Affiliate relationships may influence whether we cover a company at all, but never where it places.

How does RangeYourself align with FDA labeling?

When we describe a brand-name GLP-1 medication, we keep claims consistent with the medication’s FDA-approved labeling and indications. We do not describe off-label use as approved use, and we distinguish FDA-approved finished products from compounded preparations that are not FDA-approved.

What is the difference between compounded and brand-name GLP-1 medication?

Brand-name GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved finished products for specific indications. Compounded GLP-1 medications are prepared by licensed 503A or 503B pharmacies and are not FDA-approved finished products, even when legally dispensed. We label these pathways separately because their cost, regulatory context, and clinical considerations differ.

How does RangeYourself handle corrections?

When a factual or pricing error is identified, we correct the page promptly and note the change in the page’s update log. Material corrections — those that change a ranking, a price, or a safety-relevant statement — are dated so readers can see what changed and when.

How often is GLP-1 pricing reviewed?

GLP-1 telehealth pricing changes frequently. We aim to review core pricing pages regularly and update the GLP-1 Price Index when material changes are found. Each page carries a last-updated date that reflects when our editorial process last reviewed it — not a guarantee that a provider has not changed its terms since.

Has this content been reviewed by a clinician?

Unless a page specifically states otherwise, RangeYourself content has not been reviewed by a physician, pharmacist, or other credentialed medical professional. When credentialed review is added to a page, we identify the reviewer’s role and the scope of the review.

— RangeYourself Editorial Team